데이터를 보충하는 중입니다. 잠시 후 페이지를 새로 고치면 최신 내용을 볼 수 있습니다
88069-49-2Cc1cccc(C)c1NC(=O)CC12CCCN1CCC2.ClNZOSVDHCTCLGEB-UHFFFAOYSA-N88069-49-2DTXSID7057860CHEMBL4303511안전 정보는 참고용이며, 공급업체의 물질안전보건자료(SDS), 관련 법규 및 전문가 평가를 대체하지 않습니다.
개요Pilsicainide hydrochloride is a new pynolizidine lidocaine derivative with antiarrhythmic activity. It is the first pharmaceutical product introduced by Suntory and was solely developed in Japan. The compound is reported to be highly effective in the treatment of premature ventricular contraction. It has no anticholinergic or CNS activity and is not as likely as other class 1C antiarrhythmics to have restricted indications.
용도Pilsicainide hydrochloride has been used as a sodium channel blocker:to study its effects on electrophysiological parameters in guinea pig pulmonary vein preparationto study its effects on Ca2+release and arrhythmic events in Andersen-Tawil syndrome induced pluripotent stem cells (ATS-iPSC)-derived cardiomyocytesto study its electrophysiological effects on the guinea pig atrium
현재 필터 조건에 해당하는 반응 기록이 없습니다.
불러오는 중…